FLT3 and acute myeloid leukemia: Patients with mutations in the internal tandem duplication (ITD) region of the FMS-like tyrosine kinase 3 (FLT3) gene, one of the most common driver mutations in AML, have particularly poor prognosis following conventional chemotherapy [1, 2, 4].